Wednesday, August 30, 2017
Synthetically Produced, Predominantly EPA Omega-3 Products in Ethyl Ester or Re-Esterified Triglyceride Form
Jeffrey M. Telep
King & Spalding LLP
Amarin Pharma, Inc. and Amarin Pharmaceuticals Ireland Ltd.
Letter to Lisa R. Barton, Secretary, USITC; requesting that the Commission conduct an investigation under section 337 of the Tariff Act of 1930, as amended, regarding Certain Synthetically Produced, Predominantly EPA Omega-3 Products in Ethyl Ester or Re-Esterified Triglyceride Form. The proposed respondents are: Royal DSM NV, Netherlands; DSM Marine Lipids Peru S.A.C., Peru; DSM Nutritional Products, Parsippany, NJ, DSM Nutritional Products Canada Inc., Canada; Ultimate Biopharma (Zhongshan) Corporation, China; Marine Ingredients AS, Norwary; Marine Ingredients LLC, Mt. Bethel, PA; Golden Omega S.A., Chile; Golden Omega USA LLC, Aliso Viejo, CA; Nordic Pharma, Inc., Norway; Croda Europe Ltd., United Kingdom; Croda Inc., Edison, NJ; Tecnologica de Alimentos S.A., Peru; Nature’s Bounty, Ronkonkoma, NY; Nordic Naturals, Watsonville, CA; Pharmavite LLC, Northridge, CA; Innovix Pharma Inc., Calabasas, CA; and J.R. Carlson Laboratories Inc., Arlington Heights, IL.